September 2, 2005 Genentech issued a “Dear Healthcare Provider” letter to update physicians about cardiotoxicity in its monoclonal antibody drug Herceptin, a drug that treats breast cancer. The warning came after a study showed heart problems in 4.1% of the patients receiving Herceptin, against just 0.8% in the placebo group. More details...
